ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Implementation of Evidence-Based Strategy (PC TEACH) for the Optimization of HPV Vaccination in Rural Primary Care

Not Applicable

Recruiting

Conditions: Human Papillomavirus Infection

Interventions: Other: Educational Intervention

First Posted Date: 2024-02-13

Last Posted Date: 2024-08-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 16

Registration Number: NCT06256718

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1

Not yet recruiting

Conditions: Advanced Pancreatic Ductal Adenocarcinoma
Locally Advanced Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
Refractory Pancreatic Ductal Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8
Stage II Pancreatic Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8
Unresectable Pancreatic Ductal Adenocarcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: DDX5 Degrader FL118
Procedure: Magnetic Resonance Imaging

First Posted Date: 2024-01-16

Last Posted Date: 2024-04-12

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 84

Registration Number: NCT06206876

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Community-Based Physical Activity Intervention for Underserved Cancer Survivors

Not Applicable

Recruiting

Conditions: Hematopoietic and Lymphoid System Neoplasm
Malignant Solid Neoplasm

Interventions: Other: Exercise Intervention
Other: Questionnaire Administration

First Posted Date: 2024-01-16

Last Posted Date: 2024-12-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 200

Registration Number: NCT06206863

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors

Phase 2

Not yet recruiting

Conditions: Malignant Solid Neoplasm
Digestive System Neuroendocrine Neoplasm
Pancreatic Neuroendocrine Neoplasm
Lung Neuroendocrine Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Incomplete Freund''s Adjuvant
Procedure: Magnetic Resonance Imaging
Drug: Temozolomide
Biological: Sargramostim
Biological: SVN53-67/M57-KLH Peptide Vaccine

First Posted Date: 2024-01-11

Last Posted Date: 2024-11-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 132

Registration Number: NCT06202066

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3

Not Applicable

Recruiting

Conditions: Acute Lymphoblastic Leukemia, Pediatric

Interventions: Behavioral: Usual Care Group
Behavioral: CareMeds Intervention

First Posted Date: 2023-10-10

Last Posted Date: 2024-11-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 100

Registration Number: NCT06074666

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

PK/PD of Vaping THC-containing Liquids vs. Smoked Cannabis

Phase 1

Not yet recruiting

Conditions: Cigarette Smoking-Related Carcinoma

Interventions: Behavioral: Vape device
Behavioral: Joint
Drug: Marijuana via joint
Drug: Marijuana via vape device

First Posted Date: 2023-09-26

Last Posted Date: 2024-10-16

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 40

Registration Number: NCT06055231

A Sugar-Sweetened Beverage Reduction Intervention for Native American Men

Not Applicable

Recruiting

Conditions: Coronary Artery Disease
Diabetes Mellitus
Cardiovascular Disorder
Obesity-Related Malignant Neoplasm

Interventions: Other: Education Intervention
Other: Interview
Procedure: Discussion

First Posted Date: 2023-09-08

Last Posted Date: 2024-08-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 100

Registration Number: NCT06029517

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Early Phase 1

Recruiting

Conditions: Colo-rectal Cancer

Interventions: Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Fluorouracil
Drug: Irinotecan
Biological: Cetuximab
Biological: Bevacizumab
Procedure: Metastasectomy
Procedure: Biospecimen collection
Procedure: Computed Tomography
Biological: Panitumumbab

First Posted Date: 2023-08-25

Last Posted Date: 2024-05-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 42

Registration Number: NCT06011772

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Financial Health Educational Program for Increasing Financial Literacy Among Underserved Communities in Western New York

Not Applicable

Active, not recruiting

Conditions: Hematopoietic and Lymphoid System Neoplasm
Malignant Solid Neoplasm

Interventions: Behavioral: Behavioral Intervention
Other: Educational Intervention
Other: Questionnaire Administration

First Posted Date: 2023-08-18

Last Posted Date: 2024-07-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 99

Registration Number: NCT05997589

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients

Not Applicable

Recruiting

Conditions: Hematopoietic and Lymphoid System Neoplasm

Interventions: Procedure: Low Intensity Vibration Therapy
Procedure: Dual X-ray Absorptiometry
Procedure: Biospecimen Collection

First Posted Date: 2023-06-08

Last Posted Date: 2024-06-24

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 75

Registration Number: NCT05893940

Locations: 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Home Terms & Conditions Privacy Policy